Connect with us

News

“I’m not a bad person” – chronically ill woman convicted of growing medical cannabis

Published

on

Earlier this year Lisa Middleton was convicted of growing medical cannabis. She tells Cannabis Health why she won’t stop using the only medicine that helps manage her terminal conditions.

On Wednesday 25 April 2018 Lisa Middleton’s life changed when she woke up to a knock at the door at 9.15am.

She remembers seven police cars in the street outside and dozens of officers lining the kitchen, hallway and staircase while they searched the property where she was living in Sheffield.

Lisa, then 41, says she stayed surprisingly calm as they arrested her and took her into custody on the discovery of the 50 cannabis plants she was growing for personal, medical use.

“Looking back I should have been really scared, but because it happened as quickly as it did, I didn’t have time to think about it,” she says.

“I didn’t feel like I was a criminal.”

A few months earlier, the former hairdresser had lost her business of 10 years and had been made homeless. Living with a friend and with no income, she was forced to start growing the cannabis which she had relied on to keep her well for over 20 years.

Lisa suffers from a myriad of chronic health conditions, including severe cervical spondylosis, radial dysplasia and moderate heart failure.

She uses cannabis to manage her pain, help with circulation problems, combat nausea and boost her appetite, as well as easing her stress, anxiety and mental health issues.

“I’ve always smoked it rather than taking a supplement because it gives me more of an umbrella effect, treating everything rather than just targeting something specific,” she says.

“I knew I was breaking the law but I’d completely hit rock bottom. I felt like I had no other option.”

It was two years later when Lisa was finally charged with production of a Class B drug, under the Misuse of Drugs Act.

“It’s a hell of a long time to have it hanging over you, you’re living in limbo,” says Lisa, now 44.

“My health has deteriorated a lot in that time but I’ve got my own place now and my situation has completely changed.”

She continues: “I found it more traumatic when I got the court date, because I’ve never been in that situation in my life. You don’t know what to expect, and it’s a really scary experience.”

After her story appeared in the local press, Lisa felt some friends distanced themselves from her and instead she found support in the cannabis community, after deciding to speak openly to try and take back ownership of what had happened.

“It was worse after the arrest, I felt like a dead man walking. I thought, it’s out there I’ve got to own it and take back some control.”

She adds: “I noticed that friends distanced themselves, because of the criminality of it, even though they have known me for 15 or 20 years.

“Those in the cannabis community who I have been involved with personally, here in the UK and the US and Canada, have been the most supportive, non-judgemental people I’ve ever met.”

Some of those supporters were waiting outside Sheffield Crown Court on 15 July 2020 when Lisa was handed an 18 months suspended sentence, a 20 day rehabilitation requirement and 100 hours community service.

The Judge is reported to have acknowledged there had been a long delay before the case came to court and her previous good character.

But despite feeling incredibly relieved not to have been given a custodial sentence, she now has to face life with a permanent criminal record.

“Yes I got a suspended sentence, but I’m not free. There are certain stipulations that go along with that,” she says.

This includes weekly conversations with her probation officer to check that she is not going to reoffend, as well as partaking in a women’s rehabilitation group.

Lisa adds: “Two of my conditions are terminal, there’s no cure and ultimately they are going to take my life – going by the statistics I could be dead in two years.

“It makes you wonder, would they actually have sentenced a cancer patient?”

She now openly campaigns for a relaxation in the laws around cannabis, particularly for those like herself, who use it for medical purposes and can’t afford or don’t have access to a private prescription.

“I’m not saying I shouldn’t have been held accountable for breaking the law but I definitely believe that there needs to be a different structure in place for people like me,” she explains.

“They know that I wasn’t dealing, it was an isolated incident as a result of circumstances and I was taken through the court system in the same way as murders, rapists and violent offenders, for a victimless crime.”

She continues: “The black market is the only way we can access it, and now I’ve been criminalised for it I’m forced to go back and fund those illicit sources.”

“It’s a violation of fundamental rights for people not to be able to access the medication that works for them.

“It’s not going to be the cure for everyone, but the benefits far outweigh any negatives.”

While she would never take the risk of growing her own plants again, Lisa has no intention of stopping smoking cannabis.

She says: “Everybody knows that I’m still consuming cannabis, it’s my glue, it keeps me together.

“Technically I am a criminal because I’ve got a criminal record but we have to stop looking at people who are forced to access it illegally in that way,” she adds.

“I smoke cannabis, that doesn’t make me a bad person”

 

 

 

 

 

 

 

 

 

 

 

 

News

Ireland to fund patient’s medical cannabis up front

Campaigner Vera Twomey described “relief” that her determination has finally paid off.

Published

on

Ava Barry medical cannabis patient
Vera Twomey's daughter, Ava Barry has a severe from of epilepsy which is helped by medical cannabis

Campaigner Vera Twomey has described her “relief” as the Irish Government agrees to fund medical cannabis patient’s prescriptions up front.

Eligible medical cannabis patients in Ireland will now have their medication paid for up front, after months of pressure on the Government from campaigners. 

Health Minister Stephen Donnelly announced on Monday 19 July that the refund system for patients who obtain their prescribed cannabis-based products from the Netherlands, will now be replaced by a direct payment system.

The HSE will pay the dispensing pharmacy in the Netherlands directly, rather than the burden falling to the patients and their families, who were then required to apply for a refund.

Vera Twomey, whose daughter Ava Barry, 11, has a severe form of epilepsy known as Dravet syndrome, is among 40 patients who have now been granted an individual ministerial licence to import Bedrocan oil to Ireland.

But the family were paying 10,000 Euros up front every three months for Ava’s prescription and waiting up to five weeks for it to be refunded.

Campaigner Vera Twomey is “delighted” by the news

Twomey, who has four other children, has previously spoken of the huge financial strain this system placed on her family.

Over the last 16 months she has relentlessly called for action, making dozens of phone calls daily to politicians and lobbying ministers on social media with the backing of thousands of supporters in Ireland and across the world.

Twomey, who received a phone call from Ireland’s Prime Minister, Micheál Martin on Monday confirming the news, says she is “delighted” that her determination has finally paid off.

“There’s a sense of relief that we have accomplished this, but also a little bit of shock because we have been trying to resolve it for so long,” she told Cannabis Health.

Twomey’s activism gained national attention in 2017 when she walked from her home in Cork to Leinster House in Dublin to ask former Health Minister Simon Harris to grant access to medical cannabis for her daughter. 

Initially having to travel to the Netherlands to collect the prescription herself, during the pandemic Twomey successfully campaigned to secure the permanent delivery of Bedrocan oils for Ava and other patients.

Now she says she is looking forward to focusing on her family and putting the phone down for a while.

“I don’t think anybody who has gone through this fight, seeing the injustice that we have had to deal with could ever walk away,” she said.

“But at the same time, I’ve made a lot of sacrifices and for the moment at least, I need to give 100 percent to my other children, to do normal things and be a family.”

But the fight in Ireland isn’t over.

The Irish Government announced the provision of funding for the Medical Cannabis Access Programme (MCAP) in January – almost two years after it was introduced – but only four low dose cannabis-based medicines are covered by the programme, for people living with one of three qualifying conditions.

“There are other issues – we still need expansion and improvement in medical cannabis access, the journey is over by any means, but we’re at the beginning and getting Bedrocan recognised as a medicine that is funded up front is very important.

“I think the Irish are actually miles ahead of the British on this one and I hope [politicians] will take notice and catch up.” 

She added: “The greatest gift you’ll ever receive is to lose your fear, then you can accomplish anything with focus and determination.

“If you have the determination to keep going you will get there. It’s not going to be easy, they are not going to make it easy but it can be done.”

Patients eligible for the direct payment system are those suffering from one of three stated conditions; spasticity associated with multiple sclerosis, intractable nausea and vomiting associated with chemotherapy and severe, refractory (treatment-resistant) epilepsy. 

The HSE says it will be contacting patients directly.

Health Minister, Mr Donnelly, commented: “I am delighted that the HSE and Transvaal Apotheek in the Netherlands are implementing a new process which will give peace of mind to the seventeen patients and their families who until now have been using the refund process.”

 

 

 

 

Continue Reading

Industry

Kanabo’s cannabis vaporiser for metered dosing launches in UK

The VapePod will give thousands of UK patients access to pain relief in a metered dose.

Published

on

Kanabo cannabis Vapepod
The VapePod can administer a measured dose of cannabis extract

Cannabis company Kanabo’s new extract formula and vaporiser will give thousands of UK patients access to pain relief in a metered dose.

UK patients will be the first in Europe to have access to Kanabo’s vaporiser, the VapePod, and its new extract formula when is it delivered later this month.

The deal, in conjunction with LYPHE Group, will see patient’s of LYPHE Group’s ecosystem, including The Medical Cannabis Clinic and Dispensary Green, able to access the VapePod under the brand name NOIDECS.

Under the agreement, PharmaCann and Kanabo established a customised production line for Kanabo’s VapePods cartridges.

An alternative to cannabis flower

The VapePod is a medical-grade, handheld vaporiser which enables accurate and precise micro doses of cannabis extract, dispensing 1mg of formula for each inhalation.

This will benefit to patients as inhaling extracts rather than tinctures and oils allows for faster onset and higher bioavailability.

It will also allow clinicians to more confidently prescribe and monitor a patient’s dosage, as well as providing more accurate patient data.

Previously, cannabis patients in the UK have only been able to access medical cannabis dry flower and oil tinctures for which the majority of patients consume via inhalation due to fast onset time.

Kanabo’s medical line aims to enable patients to move away from the harmful act of smoking medical cannabis flowers as they can now take their medicine without inhaling soot, tar and carcinogens into the lungs.

Kanabo founder, Avihu Tamir

Avihu Tamir, Kanabo’s CEO, said: “The VapePod is a world first allowing specialist consultants to prescribe a metered dose of medicinal cannabis that is healthier for patients than the alternative, which is typically smoking.

“Medical cannabis is a safer alternative to the conventional opiate solutions and other pain management treatments. This announcement ensures that thousands of UK patients have access to the most effective medicinal cannabis delivery system.

“The fact that the VapePod gives exactly 1mg on every inhalation is crucial for GPs because they can prescribe an exact dose which they haven’t been able to do before. For patients who want the similarity to smoking but know they are not inhaling soot and tar. There’s also the bioavailability factor too.

“The reason GPs haven’t been prescribing is the issue of dosing and flowers – they don’t feel comfortable asking patients to smoke. With Kanabo, they can prescribe exact dosing in a safe and consistent way.”

The medical extract formula, which is based on the Israeli medical cannabis pharmacopoeia as a recommendation for the treatment of pain management, has a purity of 70 percent THC with 15 percent minor cannabinoids and terpenes.

Earlier this year Kanabo became the second cannabis company to list on the London Stock Exchange.

Dean Friday, LYPHE’s CEO commented: “Kanabo are experts in novel delivery with their VapePod greatly improving onset times, and for our chronic pain patients we now have an alternative to flower vaporisation. This is the start of a revolution in medical cannabis application and we are delighted to be supplying it under the NOIDECS brand.”

 

 

Continue Reading

Mental health

Cancer survivors turn to cannabis for physical and mental health – study

Cancer survivors are more likely to use cannabis to help pain, anxiety, sleep and nausea. 

Published

on

cancer
Cancer survivors are more likely to use cannabis to help pain, anxiety, sleep and nausea. 

Cancer survivors are frequently using cannabis to manage physical and mental health symptoms, says a new study.

Research from the US indicates that cancer survivors are more likely to use cannabis for symptoms such as pain, anxiety, trouble sleeping and nausea. 

A team of investigators analysed results from a Covid-19 cannabis health study to examine changes to cannabis use, methods of cannabis delivery, and coping strategies among cancer survivors since the pandemic.

They found that individuals with a history of cancer are more likely to report cannabis use to manage mental health and pain symptoms.

This group of people were also more likely to report fear of a Covid-19 diagnosis, compared to adults without a history of cancer.

Data was collected from 158 responses between 21 March 2020 and 23 March 2021, from cancer survivors who identified as medicinal cannabis users.

These were then compared to medicinal cannabis users without a history of cancer of the same age.

According to the study, cancer survivors were more likely to report using cannabis as a way of managing nausea/vomiting, headaches or migraines, seizures, sleep problems or as an appetite stimulant.

Specifically, self-reported symptoms most frequently managed by medicinal cannabis among respondents included anxiety and pain. 

Sixty one percent of respondents with a history of cancer used cannabis to manage anxiety symptoms and 54 percent for chronic pain.

Forty eight percent said they used it to manage depressive symptoms and 25 percent for PTSD, while smaller numbers used it for symptoms of another autoimmune disease, and irritable bowel syndrome. 

While there were no differences in how often they used cannabis or their method of administration, cancer survivors were “more likely to have an advanced supply of cannabis”. 

The findings support the need for more conversations between doctors and their patients about the use of cannabis, say those behind the study.

The authors concluded: “Overall, we observed that cancer survivors are frequently reporting the use of cannabis to manage both physical and mental health symptoms associated with their cancer diagnosis and that cancer survivors are more likely to report fear of a Covid-19 diagnosis compared to those without a history of cancer. 

“Given the frequency of mental and physical health symptoms reported among cancer survivors during the Covid-19 pandemic period, clinician–patient interactions should include questions around cannabis use, particularly those with a history of cancer.”

Continue Reading

Trending